Mark Rubinstein to Neoplasms
This is a "connection" page, showing publications Mark Rubinstein has written about Neoplasms.
Connection Strength
1.844
-
Selective suppression of de novo SARS-CoV-2 vaccine antibody responses in patients with cancer on B cell-targeted therapy. JCI Insight. 2023 Mar 22; 8(6).
Score: 0.381
-
Converting Tumoral PD-L1 into a 4-1BB Agonist for Safer and More Effective Cancer Immunotherapy. Cancer Discov. 2022 05 02; 12(5):1184-1186.
Score: 0.358
-
IL-2 and Beyond in Cancer Immunotherapy. J Interferon Cytokine Res. 2018 02; 38(2):45-68.
Score: 0.267
-
Loss of T cell-mediated antitumor immunity after construct-specific downregulation of retrovirally encoded T-cell receptor expression in vivo. Cancer Gene Ther. 2009 Feb; 16(2):171-83.
Score: 0.138
-
COVID-19 mRNA booster vaccines elicit strong protection against SARS-CoV-2 Omicron variant in patients with cancer. Cancer Cell. 2022 02 14; 40(2):117-119.
Score: 0.088
-
Identification of human CD4+ T cell populations with distinct antitumor activity. Sci Adv. 2020 07; 6(27).
Score: 0.079
-
IL6 Fuels Durable Memory for Th17 Cell-Mediated Responses to Tumors. Cancer Res. 2020 09 15; 80(18):3920-3932.
Score: 0.079
-
Anti-CTLA-4 Activates Intratumoral NK Cells and Combined with IL15/IL15Ra Complexes Enhances Tumor Control. Cancer Immunol Res. 2019 08; 7(8):1371-1380.
Score: 0.074
-
Fueling Cancer Immunotherapy With Common Gamma Chain Cytokines. Front Immunol. 2019; 10:263.
Score: 0.072
-
Recent updates in cancer immunotherapy: a comprehensive review and perspective of the 2018 China Cancer Immunotherapy Workshop in Beijing. J Hematol Oncol. 2018 12 21; 11(1):142.
Score: 0.071
-
Molecular Programming of Tumor-Infiltrating CD8+ T Cells and IL15 Resistance. Cancer Immunol Res. 2016 09 02; 4(9):799-811.
Score: 0.060
-
Effect of administration timing of postchemotherapy granulocyte colony-stimulating factor on host-immune cell recovery and CD8+ T-cell response. J Immunotoxicol. 2016 11; 13(6):784-792.
Score: 0.060
-
Exploiting IL-17-producing CD4+ and CD8+ T cells to improve cancer immunotherapy in the clinic. Cancer Immunol Immunother. 2016 Mar; 65(3):247-59.
Score: 0.058
-
Interleukin-15/interleukin-15R alpha complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells. Cancer Res. 2008 Apr 15; 68(8):2972-83.
Score: 0.034
-
Thrombin contributes to cancer immune evasion via proteolysis of platelet-bound GARP to activate LTGF-?. Sci Transl Med. 2020 01 08; 12(525).
Score: 0.019
-
Review: novel nonviral delivery approaches for interleukin-12 protein and gene systems: curbing toxicity and enhancing adjuvant activity. J Interferon Cytokine Res. 2006 Sep; 26(9):593-608.
Score: 0.008